The ARNT Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, engineered to disrupt the ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) gene. This loss-of-function model eliminates ARNT, an obligate heterodimerization partner for bHLH-PAS transcription factors such as AhR and HIF-1??, thereby abolishing both hypoxia-inducible factor (HIF) and aryl hydrocarbon receptor (AhR) transcriptional programs. The polyclonal nature provides a heterogeneous knockout population suitable for pooled functional studies, avoiding the clonal selection biases of single-cell-derived lines.
The parental A-549 cell line, established from a 58-year-old Caucasian male with lung carcinoma, exhibits adherent epithelial morphology and is a widely used model for lung adenocarcinoma. It recapitulates alveolar basal epithelial cell features and is employed in studies of epithelial-mesenchymal transition (EMT), hypoxia response, and drug metabolism. This background provides a clinically relevant platform for investigating ARNT function in oncogenic processes.
ARNT encodes a bHLH-PAS transcription factor that forms heterodimers with HIF-1?? (stabilized by hypoxia) and AhR (activated by xenobiotics like TCDD). Upon hypoxia, stabilized HIF-1?? dimerizes with ARNT, binds hypoxia response elements (HREs), and transcriptionally activates genes such as VEGFA, EPO, and GLUT1, driving angiogenesis and metabolic reprogramming. Similarly, ligand-bound AhR partners with ARNT to engage xenobiotic response elements (XREs), inducing CYP1A1 and CYP1B1 for detoxification. Knockout of ARNT disrupts these signaling cascades, providing a clean system for dissecting pathway roles.
In A-549 cells, ARNT knockout holds particular significance for lung adenocarcinoma research, where HIF-mediated hypoxia responses contribute to tumor progression, EMT, and resistance to therapy. The model enables dissecting how ARNT-dependent transcription modulates expression of downstream targets like VEGFA (angiogenesis), GLUT1 (glucose uptake), and TGFB1 (EMT), which are pivotal in the tumor microenvironment. Additionally, abrogation of AhR signaling allows examination of xenobiotic metabolism pathways influencing chemosensitivity. This cell product is instrumental for mechanistic studies linking oxygen sensing and detoxification to cancer cell behavior.
Researchers can employ these cells in a broad array of assays, including western blotting for HIF-1?? and ARNT after hypoxic exposure, RT-qPCR for VEGFA, GLUT1, and CYP1A1, HRE- or XRE-driven luciferase reporters to assess transcriptional activity, and Boyden chamber assays to evaluate migration and invasion under normoxic versus hypoxic conditions. Additional applications encompass RNA-seq for transcriptome-wide profiling, ChIP-qPCR for HRE/XRE binding, metabolic flux analysis, and ELISA for EPO secretion. These polyclonal ARNT knockout A-549 cells offer a robust platform for investigating hypoxia signaling, xenobiotic response, angiogenesis, and metabolic adaptation in lung cancer. For further information, please contact Ascent Research.
